Thrombolysis, Thrombectomy, and Antithrombotic Therapy for Acute Ischemic Stroke.

IV tenecteplase is supported by mounting evidence as a thrombolytic therapy for acute ischemic stroke.

• The article identifies tenecteplase as an evolving treatment option with growing evidentiary support
• Tenecteplase is presented as an alternative to traditional thrombolytic agents in the acute ischemic stroke setting
• Patient selection criteria for thrombolytic therapy continues to evolve alongside new evidence

Advanced neuroimaging has helped expand the time window for acute ischemic stroke therapies.

• Neuroimaging advances have broadened eligibility criteria for time-sensitive interventions
• The expanded time window applies to both thrombolytic and mechanical thrombectomy approaches
• Sophisticated understanding of neuroimaging is described as essential to appropriate patient selection

Mechanical thrombectomy indications have been broadened, particularly for patients with large core infarctions.

• Recent studies have specifically supported thrombectomy use in large core infarction cases, a population previously considered less suitable
• The application of mechanical thrombectomy continues to expand based on accumulating trial evidence
• Treatment approaches for medium and distal vessel occlusions remain an area of ongoing evolution

Early initiation of antithrombotic therapy after ischemic stroke is of paramount importance to reduce the risk of recurrence.

• Antithrombotic therapy is identified as a key component of early stroke management alongside reperfusion strategies
• The timing of antithrombotic initiation is emphasized as critical to secondary stroke prevention
• Antithrombotic therapy is discussed alongside thrombolysis and thrombectomy as a core early management strategy

Patient selection and treatment options for acute ischemic stroke are described as rapidly evolving, requiring sophisticated clinical understanding.

• The early management of acute ischemic stroke is characterized as 'complex' in the abstract
• Clinicians are described as needing 'a sophisticated understanding of the evidence supporting patient selection, use of neuroimaging, and available treatment options'
• The article frames current knowledge as a summary of an actively changing evidence base rather than a settled standard of care